Several other equities research analysts have also issued reports on SPPI. JMP Securities reissued a “buy” rating and issued a $4.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Tuesday, June 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Friday, May 27th. Cantor Fitzgerald reissued a “neutral” rating on shares of Spectrum Pharmaceuticals in a research report on Wednesday, June 8th. Finally, B. Riley dropped their price objective on shares of Spectrum Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, March 21st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $6.00.
SPPI stock traded up $0.05 on Thursday, hitting $0.89. 2,799,023 shares of the company were exchanged, compared to its average volume of 3,513,770. Spectrum Pharmaceuticals has a twelve month low of $0.60 and a twelve month high of $4.08. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.38 and a quick ratio of 2.38. The business’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.98. The stock has a market capitalization of $160.46 million, a price-to-earnings ratio of -1.01 and a beta of 2.24.
Spectrum Pharmaceuticals Company Profile (Get Rating)
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.